Momelo Nasal Spray
Mometasone Furoate + Olopatadine Nasal prep
25 mcg + 600 mcg
Incepta Pharmaceuticals Ltd.
| Pack size | 1's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 550.00 AED |
Indications
Momelo Nasal Spray is used for:
Seasonal Allergic Rhinitis, and allergy associated Rhino-conjunctivitis patients
Adult Dose
Intranasal spray
Seasonal Allergic Rhinitis
2 sprays in each nostril twice daily (morning and evening)
Hepatic impairment
Not studied; however, increasing concentrations of mometasone have been reported with severity of hepatic impairment
Child Dose
Intranasal spray
Seasonal Allergic Rhinitis and allergy associated Rhino-conjunctivitis patients
Children (6 to 11 Years of Age): The recommended dose is 1 spray per nostril twice daily (morning and evening).
>12 years: 2 sprays per nostril BID
Renal Dose
Renal impairment
Mometasone: Not studied
Olopatadine
Mild, moderate, or severe (single dose): No change in peak plasma concentration for single dose
Severe (CrCl <30 mL/min/1.73 m2) at steady-state: AUC 2-fold higher and peak plasma concentration ~10-fold higher
Administration
Contra Indications
Hypersensitivity to any ingredients of nasal spray
Precautions
Some patients may experience symptoms of withdrawal from systemically active corticosteroids. This may also unmask pre-existing allergic conditions such as allergic conjunctivitis and eczema. Epistaxis was observed in 1% of patients treated with Mometasone Furoate + Olopatadine because of Impaired Nasal wound healing.
Concurrent use of Mometasone Furoate + Olopatadine with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.
Pregnancy-Lactation
Pregnancy
Data are unavailable on use in pregnant females to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
Animal data
Olopatadine: Oral administration of olopatadine to pregnant rats and rabbits caused a decrease in number of live fetuses at maternal doses 120x and 1600x the maximum recommended human daily intranasal dose (MRHDID) on a mg/m2 basis, respectively
Mometasone: Administration of mometasone to pregnant rats and rabbits caused increased fetal malformations and decreased fetal survival and growth at doses that produced exposures 1-16x the MRHDID on a mcg/m2 or AUC basis
Lactation
Data are unavailable on presence of drug in human milk, effects on breastfed children, or on milk production
Other corticosteroids are excreted in human milk
Olopatadine has been identified in milk of nursing rats following oral administration; unknown whether topical nasal administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk
Interactions
Adverse Effects
Side effects of Mometasone Furoate + Olopatadine Nasal prep :
1-10%
Dysgeusia (3%)
Epistaxis (1%)
Nasal discomfort (1%)
Mechanism of Action
Mometasone furoate is an intranasal corticosteroid that inhibits the release of inflammatory mediators from inflammatory cells.
Olopatadine blocks the Histamine receptor-1 and stabilizes the mast cells to inhibit further release of histamine.
Note
Momelo 25 mcg + 600 mcg Nasal Spray manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Mometasone Furoate + Olopatadine Nasal prep. Momelo is availble in Bangladesh.
Farmaco BD drug index information on Momelo Nasal Spray is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.